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Vaccination  with  plasmid  DNA  against  infectious  pathogens  including  dengue  is  an active  area  of  investi-
gation.  By design,  DNA  vaccines  are  able  to  elicit  both  antibody  responses  and  cellular  immune  responses
capable  of  mediating  long-term  protection.  Great  technical  improvements  have  been  made  in  dengue
DNA  vaccine  constructs  and  trials  are  underway  to  study  these  in the  clinic.  The scope  of this  review  is
to highlight  the  rich  history  of  this  vaccine  platform  and  the  work  in  dengue  DNA  vaccines  accomplished
by  scientists  at the Naval  Medical  Research  Center.  This  work  resulted  in the  only  dengue  DNA  vaccine
tested  in  a  clinical  trial to  date.  Additional  advancements  paving  the  road  ahead  in  dengue DNA  vaccine
development  are also  discussed.
Published by Elsevier Ltd.
1. Introduction
Since the discovery in the 1990s that genetically engineered
DNA can be delivered in vaccine form and elicit an immune
response, there has been considerable progress in fully under-
standing the nucleic acid immunization technology. The ability
of plasmid DNA to activate both arms of the immune system
(i.e. cellular and humoral) against an encoded gene product has
resulted in its intensive study for vaccine development, especially
for pathogens that likely require a cellular immune response for
protection such as malaria and human immunodeficiency virus
(HIV).
Observations in the early 1990s that in vitro and in vivo gene
transfer of recombinant DNA by a variety of techniques leading to
protein expression formed the basis for the first DNA vaccine can-
didates testing in rodents and non-human primates (NHP). Some of
these approaches included retroviral gene transfer, using DNA for-
mulations with liposomes and calcium phosphase-co-precipitated
DNA [1,2]. Research done by Wolff et al. [3] showed direct intra-
muscular inoculation of plasmid DNA encoding several unique
reporter genes could induce protein expression. This study pro-
vided a strong basis for the delivery of recombinant nucleic acids
(“naked DNA”) in vivo. Continued successes included the work
of Tang et al. who showed that mice injected with plasmid DNA
encoding human growth hormone could elicit antigen-specific
antibody responses and by Robinson et al. who showed DNA vac-
cination of chickens against influenza could mediate protective
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immunity [4,5]. Another influenza DNA vaccine mouse study fur-
ther showed that both antibody and CD8+ cytotoxic lymphocyte
(CTL) responses were elicited, confirming that DNA vaccines stim-
ulate both humoral and cellular immunity [6].  These and many
other early studies provided evidence that the DNA  vaccine plat-
form was unique, and a technically simple means to induce desired
immune responses to protect against infectious diseases [7].  Given
the need for an effective dengue vaccine to generate a tetravalent
immune response, exploring the use of the DNA vaccine platform
was a logical step.
2. How DNA vaccines work
There are several factors that influence the type of immune
response induced by DNA vaccination. DNA vaccines consist of the
optimized gene sequence of interest cloned into a bacterial plas-
mid. The expression plasmid backbone and the specific nucleotide
sequences chosen from the pathogen of interest play a critical role
in the immunogenicity. The plasmid DNA is engineered synthet-
ically or by PCR for optimal expression in eukaryotic cells. It is
understood that the amount of antigen produced in vivo after DNA
inoculation is usually in the picogram to nanogram range. Since
small amounts of protein are synthesized, an efficient immune
response is dependent on the type of antigen-presenting cells
(APCs) transfected and/or the immune-enhancing properties of the
DNA itself. Research delineating the cellular mechanisms involved
in the processing and presenting of DNA vaccine-induced antigens
in vivo is described in detail by Gurunathan et al. [8] and is sum-
marized here.
The optimized gene sequence is cloned into the plasmid back-
bone and then injected into either the skin, subcutaneum or muscle.
0264-410X/$ – see front matter Published by Elsevier Ltd.
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Fig. 1. Construction of dengue-1 DNA vaccine candidates. At the top is shown a schematic representation of dengue-1 genome and the proteins encoded. Shown at the bottom
are  salient features of the vector VR1012. The segments of the dengue-1 genome cloned into each of the constructs are shown in the middle reprinted with permission, from
Raviprakash et al. [12].
The plasmid DNA is taken up by APCs and the plasmid-encoded
genes expressed intracellularly to generate the target antigens.
These host-synthesized antigens can then become the subject of
immune surveillance when associated with major histocompat-
ibility complex (MHC) class I and MHC  class II proteins of the
vaccinated person. Antigen-loaded APCs travel to the draining
lymph nodes via the afferent lymphatic vessels where they present
peptide antigens via the MHC  and the T cell receptors in combi-
nation with signaling by co-stimulatory molecules to naïve T cells.
Additionally, shed antigen can be captured by specific high-affinity
immunologlobulins (B cell receptors) expressed on the surface of
B cells, thus facilitating the induction of a B-cell response. In con-
trast to traditional vaccines, which are primarily processed via the
MHC  class II system and lead to stimulation of T-helper lympho-
cytes, the intracellular expression and processing associated with
DNA vaccines allows for presentation to the immune system in the
context of MHC  class I system, offering the stimulation of specific
cytotoxic effector T cells. The above cellular interactions initiate,
activate and expand T and B cells, and stimulate both humoral and
cellular immune responses.
3. Dengue DNA vaccine design and pre-clinical evaluation
3.1. DNA vaccine design strategies
The antibody response to dengue in humans is directed at a vari-
ety of dengue proteins including C, prM, E, NS1, NS3, NS4B and
NS5. The majority of the anti-dengue neutralizing antibody epi-
topes have been mapped to the E protein. For this reason, scientists
at the Naval Medical Research Institute chose the E gene for devel-
oping the dengue DNA vaccine construct. Studies show that the prM
gene is required for proper processing and folding of the E protein,
so the prM gene was also included [9,10].  To determine the size
of the E gene to include, four different dengue-1 constructs were
produced using the VR1012 plasmid backbone and the Western
Pacific 74 strain. Two of the constructs contained E genes lack-
ing the carboxy terminal membrane anchor sequences to facilitate
secretion of the E protein translated from the DNA vaccine. In one
construct, 20% of the E gene carboxy terminus was deleted (prM80)
and in the other, 8% was deleted (prM92) (Fig. 1). The 80% E gene
without prM was included as a candidate based on the results of
Men  et al. [11], which showed that vaccinia constructs expressing
greater than 79% E protein were immunogenic and those express-
ing proteins between 59% and 81% E were secreted extracellularly.
Smaller and larger expressed proteins were retained intracellularly.
Small animal studies were conducted to evaluate the various
DNA vaccine constructs. The constructs containing 80% of the E
gene (E80) and 100% of the E gene including the prM gene (ME100),
elicited the best neutralizing antibody responses in mice. The lat-
ter DNA vaccine construct produced a more sustained neutralizing
antibody response compared to the E80 candidate [12]. Further
evaluation of the in vitro expression of ME100 revealed the pro-
duction of virus-like particles. Based on these data, we  chose to
include the prM gene along with 100% of the E gene as the platform
for developing a tetravalent dengue DNA vaccine. The combination
of four different plasmids, each expressing prM and E proteins of a
different serotype, constitutes the tetravalent vaccine product. The
Western Pacific 74 strain was used for the dengue-1 construct and
low passage Philippine strains were used for the dengue-2, -3 and
-4 constructs.
Raviprakash and others performed parallel studies to eval-
uate the use of shuffled DNA technology to develop a single
DNA vaccine plasmid construct capable of producing tetravalent
neutralizing antibody responses. Three candidate shuffled DNA
vaccines generated using this technology elicited tetravalent neu-
tralizing antibodies in mice and protected against a lethal dengue-2
(New Guinea C strain) live virus challenge [13]. However, upon
testing in a non-human primate (NHP) model, only two of the
three shuffled vaccine candidates gave rise to tetravalent neu-
tralizing antibodies along with the tetravalent wild-type control
that consisted of a mixture of plasmids representing each serotype
[14]. Upon challenge with live dengue-1 (WestPac) and dengue-2
viruses, only partial protection against dengue-1 was  observed and
despite evidence of priming, none of the animals were protected
against dengue-2. For the dengue-1 challenge, the tetravalent mix-
ture and one shuffled vaccine candidate produced the fewest mean
days of dengue-1 viremia post-challenge. Despite observing no
protection against the dengue-2 live virus challenge, the best neu-
tralizing antibody response occurred with the control tetravalent
mixture.
To improve the immunogenicity of dengue DNA vaccines,
investigators performed studies utilizing endosomal/lysosomal
targeting of antigens expressed by the vaccine. Targeting antigens
to the endomsomal/lysosomal compartment results in the co-
localization of the expressed dengue protein with MHC  class II. This
co-localization with MHC  class II molecules presumably enhances
MHC class II presentation of antigens and neutralizing antibody
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responses. To accomplish this, the transmembrane and cytoplasmic
regions of the E gene were replaced with sequences that express
the lysosome-associated membrane protein (LAMP). Initial studies
were conducted using the dengue-2 E gene. Mice immunized with
the prME-LAMP chimera demonstrated a significantly higher anti-
dengue-2 neutralizing response compared to animals immunized
with the unmodified prME DNA vaccine construct [14,15]. Attempts
to engineer dengue-LAMP chimeras for the other serotypes resulted
in constructs that failed to track appropriately to the endoso-
mal/lysosomal compartment (unpublished results).
Based on the studies described above, we chose to take for-
ward for further non-human primate testing, the tetravalent
dengue DNA vaccine consisting of DNA plasmids for each serotype.
Given the improved neutralizing antibody responses seen in mice,
researchers chose the dengue 2 prME-LAMP chimera for the
dengue-2 component of the tetravalent dengue DNA vaccine.
3.2. Pre-clinical non-human primate studies
Although no perfect animal models of human dengue disease
exist, NHPs can be used to evaluate immunogenicity and allow
immunization schedules that are more aligned to the frequency
anticipated in humans. Virus neutralizing antibodies are readily
detected in several NHP species and viremia can be measured post-
challenge as a surrogate of protection.
Three studies with the dengue 1 monovalent DNA vaccine
(D1ME100) provided the basis for advancement into the clinic.
In the first study [16], eight rhesus macaques (Macaca mulatta)
received 1.0 mg  of plasmid DNA intramuscularly (IM) in phosphate-
buffered saline (PBS) at months 0, 1 and 5. Control animals (n = 3)
received plasmid without dengue genes. All vaccinated animals
seroconverted by ELISA, and neutralizing antibodies were produced
in 7 of 8 vaccinated NHPs and none of the controls. These animals
were challenged with wild type dengue-1 (strain WestPac 74) 4
months after the third dose of vaccine (9 months after first dose).
After challenge, 4 of 8 vaccinated animals were completely pro-
tected from viremia and the remaining four had reduced viremia.
T-cell stimulation was examined by stimulating peripheral blood
lymphocytes from two naïve primates and two vaccinated primates
and measured by in vitro secretion of IFN-gamma by ELISA. By this
method, T-cell responses were undetectable in the vaccinated ani-
mals prior to the live virus challenge. Because the ELISA method
was less sensitive than the ELISpot and intracellular cytokine assays
(not available at that time), low level memory anti-dengue T-cell
responses may  have gone undetected. After live virus challenge,
robust anti-dengue-1 T-cell responses were demonstrated.
The second study evaluated the D1ME100 vaccine in New World
Owl monkeys (Aotus nancymae)  [17]. Six animals received 1.0 mg
of plasmid DNA (three IM and three ID) at months 0, 1 and 5.
Control monkeys (n = 3) received vector plasmid alone. All six vac-
cinated animals produced neutralizing antibodies. Monkeys were
challenged with wild type dengue-1 virus at 6 months after the
third vaccine dose (11 months after first dose). After challenge, 2 of
6 animals were completely protected from viremia and the remain-
der had reduced viremia. These studies with initial formulations
were a successful test of concept that dengue DNA vaccines can
protect NHPs from challenge with wild type virus.
A third NHP study was conducted in Aotus monkeys to enhance
neutralizing antibody responses to the D1ME100 vaccine [18]. Four
strategies were evaluated: (1) co-immunization with a plasmid
expressing Aotus GM-CSF gene, (2) co-immunization with a plas-
mid containing human immunostimulatory sequences (ISS), (3)
co-immunization with both the GM-CSF gene and ISS, and (4)
delivery of vaccine using the needle-free Biojector® system. Immu-
nization with the various vaccine formulations, either by needle
injection or Biojector®, led to neutralizing antibody (PRNT50 group
means ranging from 1:156.2 to 1:357.5) that was stable for up to 6
months after vaccination. Furthermore, 6 of 7 monkeys (85%), and
7 of 8 monkeys (87%) receiving this formulation were completely
protected from viremia when challenged with a WestPac dengue-1
strain, 1 and 6 months after vaccination, respectively. Neutralizing
antibody levels were higher in the group that was  immunized using
Biojector® compared to levels obtained using needle and syringe
(anti-dengue-1 PRNT50 group mean, 1:307.8 versus 1:161.8). This
was a significant improvement compared to our previous studies
with D1ME100, thus it was  the first dengue DNA vaccine selected
for evaluation in humans.
4. Dengue DNA vaccine clinical trials
The accomplishments of the early animal studies and the
advancement of plasmid DNA technology led to the first human
clinical trial of DNA vaccination against HIV-1 infection in 1998
[19]. Since then, other DNA vaccines for infectious diseases have
been evaluated in published Phase 1 studies including other HIV-1
constructs, an Ebola virus candidate [20,21] as well as a West Nile
virus (WNV) vaccine [22]. The West Nile vaccine candidate encoded
the prM and E glycoproteins identical to that in the WNV  isolate
from the epidemic experienced in the U.S. in 1999. The vaccines
were well-tolerated and safe. All subjects receiving three doses
mounted a neutralizing antibody response (PRNT50 peak = 1:128),
however when measured using the more stringent PRNT75, there
were minimal responses (peak = 1:32). When WNV  reporter-virus
particles were used to measure antibody-mediated neutralization
using a Raji B lymphoblastoid (surrogate) cell line that expressed
the WNV  attachment factor CD209L (DC-SIGNR), the neutralizing
antibody titers were magnified. Vaccine-specific T-cell responses
specific for WNV  insert-specific peptide pools as measured by
ELISpot assays showed the majority of vaccinees mounted both
CD4+ and CD8+ T-cell responses.
To date, our Phase 1 study is the only published dengue DNA
vaccine human clinical trial [23]. The dengue-1 D1ME100 vaccine
construct evaluated in the trial was  similar to the WNV  DNA vaccine
described above (DNA plasmid expressing prM and E) and was  also
administered intramuscularly using Biojector®.
To evaluate the pre-clinical safety of D1ME100 prior to begin-
ning the clinical trial, a 61-day single-dose IM biodistribution study
was performed in CD-1 mice (Gene Logic Laboratories Inc., Study
No. 1381-101). Two groups of CD-1 mice (33 mice total) were given
either 50 l of sterile PBS (10 mice) or 100 g in 50 l PBS (23
mice) of D1ME100 IM.  No significant changes were noted among
the groups with regard to mortality, clinical signs of toxicity, body
weights, body weight gains, or food consumption. Distribution
studies showed the presence of D1ME100 in the injection site mus-
cle at the day 62 necropsy, but showed a progressive decrease in
copy number per microgram of genomic DNA between necropsies.
Integration of DNA from the vaccine into host chromosomal
DNA resulting in neoplastic transformation of cells has been a the-
oretical risk. In the above bio-distribution studies of D1ME100, no
evidence of integration was  observed through study day 62 in CD-1
mice. Examination of in vivo genomic DNA integration of plasmid
DNA sequences (unrelated to the NMRC vaccine) into host genomic
DNA was  conducted in mice by Martin et al. [24]. Using quantita-
tive PCR amplification, integration of plasmid DNA was estimated
to be a low probability event, occurring 3000 times lower than the
spontaneous mutation rate. Subsequently, Wang et al. [25] demon-
strated negligible uptake occurs in mice when DNA is administered
via electroporation. To date, clinical Phase 1 human trials of DNA
vaccines (including D1ME100) have not demonstrated the occur-
rence of either integration or neoplastic transformation in human
recipients.
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Fig. 2. Development plan for dengue DNA vaccines. The arrows from the tetravalent dengue DNA show the various approaches that will be explored to enhance the
immunogenicity of the tetravalent vaccine.
A toxicity study was performed in New Zealand white rab-
bits (Gene Logic Laboratories Inc., Study No. 1381-102). The study
was designed as a 14-week repeat-dose, where groups of rab-
bits (8 animals/sex/group) were used with one group receiving
2.5 mg  of the vaccine IM,  the other receiving 5.0 mg  IM,  and the
control group receiving sterile PBS. Injections were repeated on
days 29, 57, and 85. No significant changes were noted among the
groups in mortality, cage side observations, clinical observations,
Draize observations, body weights, body weight changes, food
consumption, ophthalmologic, clinical pathology, bone marrow,
or immunologic assessments, organ weights, organ rations, gross
pathologic, or histopathologic observations. Under these study con-
ditions, repeated IM administration of doses of up to 5.0 mg  of
D1ME100 to New Zealand White rabbits also failed to show any
overt systemic or local toxicity.
For the Phase 1 clinical trial, D1ME100 DNA vaccine doses of
1.0 mg/ml  and 5.0 mg/ml  were studied in healthy flavivirus-naïve
subjects administered at 0, 1 and 5 months. Anti-dengue 1 plaque
reduction neutralization titers (PRNT50) ranged from 1:11 to 1:135,
with a median maximum titer for the five responsive subjects in
the high dose group of 1:50. No neutralizing antibody responses
were detectable in subjects who received the low dose vaccine.
To evaluate cell-mediated immunity, IFN- levels were assessed
against E proteins from all four dengue virus serotypes. Responses
were detected in 50% (4/8) and 83.3% (10/12) of subjects in the low
and high dose group, respectively.
The vaccine was well-tolerated without any severe vaccine-
related adverse events reported. Mild pain or tenderness and
swelling were the most commonly reported symptoms post-
vaccination. Despite the low PRNT50 titers, overall immune
responses and excellent safety profile provided evidence that a
dengue DNA vaccine platform is a viable alternative to other vac-
cines.
5. The future for dengue DNA vaccine development
To date, the immunogenicity of DNA vaccines has not been
comparable to vaccines developed using more conventional
methodologies such as purified inactivated vaccines, live atten-
uated vaccines and recombinant protein vaccines. The ease of
manufacture and stability of DNA vaccines continue to make this
development approach attractive, but to be a viable option, the
immunogenicity must be improved. Fig. 2 outlines the develop-
ment plan for dengue DNA vaccines. Enhancements can be made
either by improving the DNA construct itself, co-immunization
with adjuvants, and/or finding alternate routes of administration
that promote more efficient vaccine uptake by antigen-presenting
cells and greater expression of encoded proteins.
Improvements in the plasmid backbone of DNA vaccines include
the use of different promoters, the inclusion of immunostimula-
tory sequences, and more efficient signal sequences. In addition
to plasmid backbone alterations, genes that express the desired
antigen are routinely codon-optimized for better expression in
humans. Early pre-clinical small animal and non-human primate
studies showed the benefit of including immune-enhancing CpG
sequences [26] and tissue plasminogen activator leader sequences
in DNA immunization [27]. However, these modified vaccines failed
to show adequate immunogenicity when evaluated in human clin-
ical trials [28,29]. CpG motifs continue to be explored for their
immune modulating characteristics [30].
Ledgerwood et al., recently published the results of a Phase 1
study of a WNV  DNA vaccine containing a promoter that was mod-
ified to include regulatory sequences from the long terminal repeat
segment of HTLV-I [31]. These sequences enhance transcription and
posttranscriptional events. This DNA vaccine modification resulted
in significant increases in T cell responses to the prM protein and
in antigen-specific CD 8 T cell responses to the E protein compared
to the unmodified WNV  DNA vaccine. Phase 2 studies to evaluate
protection against disease are underway.
DNA vaccine efforts targeting cancer demonstrated the utility of
co-administering the vaccine with lipid-based compounds. Target-
ing infectious disease agents, this approach resulted in enhanced
immune responses to influenza, tuberculosis, HIV, anthrax and
Japanese Encephalitis. Vaxfectin®, a proprietary lipid adjuvant
manufactured by Vical Inc. has been studied with DNA vaccines
for several infectious pathogens. A Phase 1 human clinical trial of a
Vaxectin®-formulated H5N1 DNA vaccine showed that the vaccine
was well tolerated and induced neutralizing antibody responses
comparable to protein-based H5N1 vaccines [32]. No comparison
was made to the DNA vaccine administered without Vaxfectin®.
With the less than optimal neutralizing antibody response to
the prototype dengue-1 DNA vaccine (D1ME100) in humans, we
sought to enhance the immunogenicity of vaccine by formulating
it with Vaxfectin®. Pre-clinical non-human primate studies using
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a Vaxfectin®-formulated tetravalent dengue DNA vaccine demon-
strated an enhanced anti-dengue neutralizing antibody response
against each of the four dengue virus serotypes (unpublished
results) compared to the unformulated vaccine. Based on these
results, efforts are underway to evaluate the formulated tetravalent
vaccine in a Phase 1 clinical trial.
The route of administration may  have a significant impact
on the immunogenicity of a particular DNA vaccine. Most of
the pre-clinical and clinical studies of DNA vaccines involved IM
administration by needle or the needle-free Biojector® device.
Intradermal administration has also been used with variable suc-
cess. Recently, electroporation has received attention as a route
of administration for improved immunogenicity [33]. The ques-
tion remains though whether this method of vaccine delivery is
conducive for large public health immunization campaigns. Many
resource-poor areas would likely have difficulties with any vaccine
that relies on an expensive technically advanced delivery system.
The testing of combination vaccines delivered together or in a
heterologous prime-boost regimen has recently been studied for
many infectious pathogens including dengue. Scientists at NMRC
have maintained close collaborations with U.S. Army researchers
at the Walter Reed Army Institute of Research (WRAIR) for years.
Mouse and NHP studies including the WRAIR purified inactivated
dengue (PIV) vaccine in combination with the NMRC DNA dengue
vaccine have shown promising results [34,35]. These have led to the
planning and regulatory preparations for human trials using prime
boost strategies incorporating the dengue DNA, PIV and WRAIR
live-attenuated vaccine candidates.
6. Conclusion
The field of DNA vaccination has advanced significantly during
the last two decades. Better-designed constructs and promoters
and novel delivery technologies tested in animals and advanced
in the clinic are evidence that the field is exciting. Our upcom-
ing tetravalent dengue DNA vaccine formulated with Vaxfectin®
Phase 1 trial and the trials studying prime-boost approaches with
DNA candidates will be pivotal in determining if this platform will
provide realistic possibilities for a dengue vaccine in the future.
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